You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 23, 2024

~ Buy the SOLOSEC (secnidazole) Drug Profile, 2024 PDF Report in the Report Store ~

CLINICAL TRIALS PROFILE FOR SOLOSEC

✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for SOLOSEC

Subscribe to access the full database, or Subscribe
Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT03935217 ↗	A Phase 3 Study of Solosec® for the Treatment of Trichomoniasis	Completed	Lupin Research Inc	Phase 3	2019-04-23	This is a Phase 3, multi-center, prospective, randomized, placebo-controlled, delayed treatment, double-blind, study to evaluate the effectiveness, and safety of a single, oral dose of Solosec® containing 2 grams of secnidazole in female patients with trichomoniasis.
NCT03937869 ↗	Evaluate the Safety of a Single Oral Dose of Solosec™ (Secnidazole) 2g for the Treatment of Adolescent Girls With BV	Completed	Lupin Research Inc	Phase 4	2018-11-28	A multi-center, open-label study to evaluate the treatment of one oral dose of 2g Solosec™ (Secnidazole) in adolescent girls with BV
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Start Date	>Summary

Clinical Trial Conditions for SOLOSEC

Condition Name

Chart
Table

Condition Name for SOLOSEC
Intervention	Trials
Bacterial Vaginoses	1
Trichomonas Infection	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Condition MeSH

Chart
Table

Condition MeSH for SOLOSEC
Intervention	Trials
Vaginosis, Bacterial	1
Vaginal Diseases	1
Trichomonas Infections	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Locations for SOLOSEC

Trials by Country

Map
Table

Trials by Country for SOLOSEC
Location	Trials
United States	17
This preview shows a limited data set Subscribe for full access, or try a Trial

Trials by US State

Map
Table

Trials by US State for SOLOSEC
Location	Trials
Tennessee	2
Florida	2
South Carolina	1
Pennsylvania	1
North Carolina	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Progress for SOLOSEC

Clinical Trial Phase

Chart
Table

Clinical Trial Phase for SOLOSEC
Clinical Trial Phase	Trials
Phase 4	1
Phase 3	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Status

Chart
Table

Clinical Trial Status for SOLOSEC
Clinical Trial Phase	Trials
Completed	2
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Sponsors for SOLOSEC

Sponsor Name

Chart
Table

Sponsor Name for SOLOSEC
Sponsor	Trials
Lupin Research Inc	2
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Sponsor Type

Chart
Table

Sponsor Type for SOLOSEC
Sponsor	Trials
Industry	2
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.